European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2006
Therapeutic options: Addressing the current dilemma.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dinan Timothy
Аннотация
The main therapy for the symptomatic management of generalized anxiety disorder (GAD) is pharmacotherapy, although comprehensive management methods also include psychotherapeutic interventions. Traditionally, treatments including anxiolytics and antidepressants have been used in GAD management, but prescribing physicians have more recently moved towards using selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs). Indeed, newer medicines have been shown to be as effective as older treatments, but with improved safety and tolerability. Although the best way to treat GAD has yet to be established, these patients clearly need long-term supervision. Ideally, physicians should prescribe treatment with the purpose of ultimately eliminating symptoms and re-establishing normal function. To achieve this goal, physicians need a more effective, faster acting, safer, and better tolerated drug than the many existing GAD treatments.